Matching articles for "RSV"
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 2, 2024; (Issue 1710)
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
In Brief: RSV Vaccine (Arexvy) for Ages 50-59
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD)...
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD) caused by RSV. It was previously
approved only for adults ≥60 years old. Two other
RSV vaccines have received FDA approval: Abrysvo,
a recombinant vaccine that is licensed for use in
adults ≥60 years old and in pregnant women at
32-36 weeks' gestation to prevent RSV-associated
LRTD in their infants, and mResvia, an mRNA vaccine
recently licensed for use in adults ≥60 years old that
will be available for the 2024-25 RSV season.
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
New 2023-2024 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech
(Comirnaty) and...
New 2023-2024 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech
(Comirnaty) and that more
closely target currently circulating variants have
been licensed by the FDA for use in persons ≥12 years
old and made available under FDA Emergency Use
Authorizations (EUAs) for use in persons 6 months
to 11 years old. The bivalent (original and Omicron
BA.4/5) formulations of the Pfizer and Moderna
vaccines are no longer authorized for use in the US.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • October 2, 2023; (Issue 1686)
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • September 18, 2023; (Issue 1685)
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Antiviral Drugs
The Medical Letter on Drugs and Therapeutics • March 1, 2013; (Issue 127)
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2010; (Issue 98)
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been...
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been approved
by the FDA. Vaccines used for the prevention of viral
infections are discussed in another issue of Treatment
Guidelines.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2007; (Issue 59)
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA....
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the "Adult Immunization" issue of Treatment Guidelines.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • April 1, 2005; (Issue 32)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the FDA.
Drugs for Pneumonia
The Medical Letter on Drugs and Therapeutics • September 1, 2003; (Issue 13)
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • February 4, 2002; (Issue 1123)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some new recommendations for old drugs have been added.
Synagis Revisited
The Medical Letter on Drugs and Therapeutics • February 19, 2001; (Issue 1098)
Palivizumab (Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and...
Palivizumab (Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • December 3, 1999; (Issue 1067)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's]...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • August 1, 1997; (Issue 1006)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.